Locally Advanced Rectal Cancer Clinical Trial
Official title:
Phase 1 Study of Mitochondrial Energetics After Long Course Chemoradiotherapy and a Short Term Exercise Programme in Locally Advanced Rectal Cancer Patients - A Randomized Controlled Trial.
The present study is a randomised control trial investigating the effects of a short six
week exercise training program in rectal cancer patients following neoadjuvant
chemoradiotherapy prior to elective rectal cancer surgery.
Twelve patients will be randomised (1:1) to an intervention and a control group. The
patients randomized to the intervention group will attend a total of 18 tailored exercise
sessions (Three 40 minute sessions for six weeks) after their 6 weeks of chemoradiotherapy
treatment. Where possible the exercise training sessions will be arranged to fit in with
other appointments at the hospital. Patients randomized to the control group will be
unsupervised. They will only attend an extra 3 sessions were a cardiopulmonary exercise test
and VO2 Kinetics test will be performed. Patients will also be invited to attend 3 health
related quality of life interviews at week 0, 3 and 6 during their exercise programme. These
appointments will be directly before or after their exercise sessions to minimise hospital
attendence.
Following surgery only routine clinically relevant observational data will be collected.
These data will relate to hospital length of stay, the level of care required following
surgery, post-operative morbidity survey (POMS) and the recovery process. Most of this
information can be accessed from patient notes and on the electronic patient records system.
This is a subgroup RCT of patients in a larger interventional trial (6 control and 6
exercise intervention patients) will be asked to consent separately for the the
31-Phosphorus Magnetic Resonance Spectroscopy (31P MRS) scans and the blood samples.
HYPOTHESIS
1. Interval exercise training will maintain or improve fitness (measured by anaerobic
threshold) in patients undergoing neoadjuvant chemoradiotherapy.
2. Interval exercise training is safe and feasible in patients undergoing neoadjuvant
chemoradiotherapy awaiting rectal cancer resection.
3. Interval exercise training will improve other measures of physical fitness measured in
the CPET and the oxygen uptake kinetics test.
4. Interval exercise training will improve quality of life in patients undergoing
neoadjuvant chemoradiotherapy.
5. Improvements in physical fitness will reduce postoperative complications following
major rectal cancer surgery.
6. Does physical activity, measured by Sensewear Pro 3 activity monitors, decrease during
neoadjuvant chemoradiotherapy and can this decrease be attenuated by an exercise
training program?
7. Can we find an optimal time for surgery when fitness and cancer downstaging are at
their best?
HYPOTHESIS for Mechanism Pilot Study
1. To explore the exponential rate constant of post-exercise phosphocreatine recovery.
2. To explore the alteration in cellular and mitochondrial energetics eg. Change in
mitochondrial numbers, change in mitochondrial activity and respiration.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of T3N+ rectal cancer - above age of 18 - able to conduct a cardiopulmonary exercise test on a cycle ergometer Exclusion Criteria: - unable to conduct a cardiopulmonary exercise test on a cycle ergometer - metastatic disease |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
United Kingdom | Aintree University Teaching Hospitals NHS FT | Liverpool | Merseyside |
Lead Sponsor | Collaborator |
---|---|
Michelle Mossa | University of Liverpool |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Exponential rate constant of post-chemoradiotherapy and post-exercise phosphocreatine recovery. | Between baseline and week 0 and between week 0 at week 6 post-NACRT | No | |
Secondary | Alterations in mitochondrial energetics post-chemoradiotherapy and exercise | Changes in 31- Phosphoromagnetic resonance spectroscopic (31-PMRS) ATP:ADP ratio | Between baseline and week 0 and between week 0 and week 6 post-NACRT | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05079438 -
Dendrobium Huoshanense Suppository in Rectal Cancer
|
Phase 3 | |
Recruiting |
NCT02964468 -
Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer
|
N/A | |
Not yet recruiting |
NCT05507112 -
TIME in Immunotherapy Combined With nCRT for Rectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05998122 -
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
|
Phase 2 | |
Completed |
NCT04324567 -
Inflammation After Laparoscopic Robot-assisted Surgery for Locally Advanced Rectal Cancer
|
||
Recruiting |
NCT05412082 -
SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer
|
Phase 1 | |
Recruiting |
NCT05980689 -
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
|
Phase 2 | |
Recruiting |
NCT02605265 -
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
|
Phase 3 | |
Terminated |
NCT02151019 -
Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05086627 -
Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05076305 -
PelvEx 4: Advanced Pelvic Malignancy and the Role of the Multi-disciplinary Team Meeting
|
||
Recruiting |
NCT03824899 -
UGT1A1 Combined With Pharmacokinetics of SN-38 in CPT-11-based CRT in Patients With Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT05845268 -
Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal Cancer
|
Phase 2 | |
Completed |
NCT03392584 -
Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters
|
||
Terminated |
NCT04177602 -
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT05646511 -
Total Neoadjuvant Therapy of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer (ENSEMBLE)
|
Phase 3 | |
Terminated |
NCT02290574 -
Efficacy of NeoThermo-Radio-chemotherapy for LA Rectal Cancer Before Laparoscopic TME: Prospective Phase II Trial
|
N/A | |
Recruiting |
NCT03702985 -
Radiation-protection Effect of Amifostine in Locally Advanced Rectal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05877352 -
Intraoperative Electron Radiotherapy in Rectal Cancer - A Feasibility Trial
|
N/A | |
Not yet recruiting |
NCT06375434 -
Correlation Between Gut Microbiota and Radiosensitivity of Rectal Cancer
|